TRCT
IMPL

Tower Research Capital (TRC)’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Tower Research Capital (TRC)’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,936
Closed -$3.41K – 6293
2023
Q3 		$3.41K Buy
7,936
+3,936
+98% +$3.78K ﹤0.01% 5008
2023
Q2 		$5.08K Buy
4,000
+2,962
+285% +$4.49K ﹤0.01% 4865
2023
Q1 		$1K Buy
+1,038
New +$2.48K ﹤0.01% 5690
2022
Q4 		– Sell
-10,245
Closed -$50K – 6599
2022
Q3 		$50K Buy
10,245
+9,035
+747% +$69.2K ﹤0.01% 3160
2022
Q2 		$11K Sell
1,210
-2,407
-67% -$17.6K ﹤0.01% 4406
2022
Q1 		$23K Buy
3,617
+188
+5% +$1.42K ﹤0.01% 3417
2021
Q4 		$30K Buy
3,429
+515
+18% +$5.14K ﹤0.01% 3239
2021
Q3 		$35K Buy
2,914
+2,048
+236% +$29.7K ﹤0.01% 3252
2021
Q2 		$8K Buy
+866
New +$10.3K ﹤0.01% 4522

Other funds holding IMPL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Tower Research Capital (TRC)'s IMPL Position: Q4 2023 in Review

Tower Research Capital (TRC) sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 7,936 shares — an estimated $3.41K sold.

Tower Research Capital (TRC) first reported a position in IMPL in Q2 2021 and held it in 9 quarters. The position peaked at $50K in Q3 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

  • Tower Research Capital (TRC) reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 7,936 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $3.41K.
  • Tower Research Capital (TRC) first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 9 quarters.
  • Tower Research Capital (TRC)'s Impel Pharmaceuticals Inc. Common Stock position peaked at $50K in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.